
usd feb pm et
summari lead develop manufactur provid analyt instrument
complex servic life scienc drug discoveri industri applic
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb pm stock trade
broad product line geograph coverag span
life scienc health care industri market
singl custom account total
revenu reduc risk view balanc
intens competit industri compani
oper howev cut edg technolog
requir remain relev present
technolog risk obsolesc fact
sale growth slow yoy
first nine month
patheon acquisit
longer provid inorgan boost life
scienc total revenu analyt
instrument led way
yoy growth respect driven robust
demand biopharmaceut custom
china-bas buyer sale china
remain strong growth
despit concern trade war think
reflect strength product line
lack viabl domest competitor
addit robust revenu growth
improv pre-tax incom margin rose
see partial
result make good forecast
synergi patheon expect
margin improv along line
also impress quickli
reduc debt follow acquisit
ebita-to-interest even better
prior acquisit given
healthi leverag would
surpris hear anoth major deal
announc
like dual strategi invest heavili
intern innov organ growth
pursu leverag scale
line invest new technolog
unriv view estim
combin capital-expenditure spend
approxim next three largest
competitor combin front
conserv debt acquir improv
margin pay debt repeat
sinc made acquisit worth
roughli present invest
capit steadili increas pre-tax
margin result
roughli basi point increas roe
expect accret resum next
year leverag restor
target ep
estim long-term forward price-to-earnings
averag expect continu gain
market share conveni
broad servic offer custom risk
view includ slump end market
contract intern market lack
new candid
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview thermo fisher scientif lead provid life scienc tool
servic broad array end market includ pharma/biotech compani academ govern
institut diagnost health care compani industri appli scienc compani
product servic includ laboratori analyt instrument biochem reagent laboratori
medic consum softwar servic research analysi discoveri diagnosi
product instrument scientif innov around world divers field drug discoveri
environment regulatori complianc food safeti think market repres combin
billion billion annual marketplac think largest compani within marketplac
broadest product offer geograph coverag
life scienc solut sale compris primarili acquir
busi see corpor strategi focus genet sequenc instrument servic
analyt sale compris primarili legaci thermo electron busi
merger focus primarili develop manufactur analyt system
instrument compon segment also provid softwar solut monitor collect
specialti diagnost sale focus diagnost instrument assay use
determin content qualiti molecul
laboratori product servic sale compris primarili legaci fisher scientif
busi focus lab equip consum well biopharma outsourc servic
corpor strategi think strength lie extens product offer geograph
coverag one-stop shop strategi allow scientist research health care profession
order divers product need time cost-effect manner one sourc
continu expand product portfolio extens intern develop
extern growth via acquisit estim combin capital-expenditure roughli
line next three largest competitor combin also proven extrem effect
streamlin oper acquir firm period saw execut worth
acquisit steadili increas ebita margin period recent
notabl acquisit includ august acquisit patheon billion septemb
acquisit fei compani billion march acquisit affymetrix billion
februari acquisit billion
lead provid life scienc tool servic includ next gener genet
sequenc acquisit greatli expand life scienc segment revenu
enabl quickli gain sizabl market share fast-grow genet sequenc
market although expect remain clear leader life scienc highest oper
margin among segment expect continu materi contributor organ growth
patheon ebita margin stand-alon busi lower compani averag
appear execut cost synergi overal ebita margin maintain
august acquisit also see strong revenu growth opportun patheon
clinic trial servic bioproduct technolog expect improv margin scale grow
competit landscap life scienc tool servic scientif product servic
marketplac highli fragment highli competit think may competit advantag
peer due purchas power oper leverag broad product offer
water corp among privat held firm primari competitor
financi trend sale increas billion billion repres
five-year compound annual growth rate compound-annual-growth-rate prolif acquir acquisit
aid sale growth howev compani also streamlin variou oper divest
busi well ebita margin increas adjust ep
rose repres compound-annual-growth-rate
board
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc januari technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
lst sub-industri
next month think among
fastest-grow sub-industri within health
care sector driver earn growth
sub-industri next year
view strong growth public fund
health care research increas
spend biopharmaceut compani
budget nation institut
nih grew rapidli last three year
materi increas fund academ
govern lab turn drive sale
growth lst compani gener
materi portion revenu lab
fy nih budget grew
fy
budget increas aid lst
sub-industri sale growth
forecast
expect anoth materi nih budget
increas fy support robust
demand sub-industri product
year ahead well
addit public-fund health care
research expect larg increas privat
biopharmaceut spend drive sale
growth life scienc tool servic
sub-industri month end septemb
estim spend
increas year-over-year
spend biotech
depart research tool product
well contract research servic
 growth continu year ahead
translat continu solid sale growth
lst sub-industri
care research type prolifer
around world particularli china
emerg market turn
drive strong intern sale growth
establish life scienc tool servic
compani china particular
view howev tailwind may moder
china face slowdown econom
growth use five largest compani
lst sub-industri proxi estim
averag growth sub-industri
china-deriv sale slow
year-over-year
long-term though think china
major emerg market nation like india
need continu rapidli increas health care
expenditur parallel grow
middl class turn like continu
support strong sale growth lst
sub-industri see happen despit
potenti neg impact
import/export tariff limit
large-scal supplier option
state-of-the-art lst product outsid
compani notabl except
switzerland-bas roch
 life
rise
 life
drop
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra maintain buy opinion share thermo fisher
scientif inc keep target
ep estim long-term averag forward price-to-earnings
expect above-averag ep growth lower ep estim
keep ep vs beat forecast
report strong view top-lin growth yoy
driven solid growth across four oper segment life scienc
total revenu fastest grow
yoy respect driven continu robust demand
biopharmaceut custom china-bas buyer china sale growth
total remain strong yoy expect growth
market also improv pre-tax incom margin roughli bp yoy
expect improv margin trend continu
patheon acquisit integr major plant machineri
invest made harvest /colin scarola
fisher scientif keep target price
slightli peer ep estim
discount growth acquisit ep vs
ahead estim sale rose organ growth
contribut acquisit ahead sale growth forecast
pharmaceut biotech end market remain robust see
compani gain market share expand valu proposit offer
recent addit pantheon encourag robust organ
growth rate anticip among highest life scienc space
quarter see sale growth driven new product innov
signific grow market share emerg market particularli
china howev anticip oper margin declin due
integr pantheon lower margin howev look better
margin /jeffrey loo cfa
et cfra add thermo fisher scientif high-qual
capit appreci port largest life
scienc compani unmatch product offer along signific
geograph presenc view compani oper four busi segment
analyt instrument life scienc solut specialti diagnost
laboratori product also maintain lead market share mani
market grown well-balanc capit deploy strategi
includ acquisit supplement organ growth well stock buyback
dividend replac ci high-qual capit appreci
scientif inc keep target
slightli above-p averag ep estim expect
above-averag growth initi ep estim ep
vs beat estim report strong quarter
view top-lin growth yoy fuel patheon
acquisit last year acceler organ growth segment
especi impress acceler organ sale growth life
scienc yoy believ indic
grow market share rapidli grow field especi import
given life scienc largest segment profit total
also improv oper margin bp yoy led success sg
contain effort expect margin improv next year
strong track record streamlin second year larg
acquisit case patheon next year /colin scarola
buy strong buy keep target
slightli below-p averag ep estim see rapid
organ acquisit growth recent year becom difficult
sustain due greatli increas scale follow patheon
acquisit august rais ep estim
opinion chang relat valuat share price increas
year-to-d push forward price-to-earnings multipl well beyond
averag respect expect growth remain strong particularli
china sale grow becom cautiou
valuat given larg scale like make meaning growth harder
achiev futur year remain support dual-strategi
invest heavili intern innov pursu acquisit track
record increas seri three major acquisit
past five year impress /colin scarola
et cfra reiter strong buy opinion share thermo
fisher scientif rais target
slightli peer forward ep estim
discount growth acquisit ep vs
ahead view rais ep estim
ep estim sale contribut acquisit
rose ahead growth forecast organ growth robust
growth broad-bas across end market geographi life scienc
analyt instrument specialti diagnost lab
product includ patheon acquisit sale china rose
see posit across divers end market geographi key
strength attract client across globe main supplier
instrument consum launch new product includ
q-exact uhmr protein research immunoassay analyz
see contribut growth /jeffrey loo cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
